37 results about "Circumsporozoite protein" patented technology

The invention is an DNA vaccine and method of use thereof for modulating the immune response against the circumsporozoite protein (CSP) of malaria parasites, using the CR2 binding motifs of C3d, especially p28.

Described in this application is a synthetic P. vivax circumsporozoite protein useful as a diagnostic reagent, for antibody production, and as a vaccine protective against infection with any strain of P. vivax.

The present invention relates to processes for purifying high-quality recombinant Plasmodium falciparum circumsporozoite protein at high yields.

A composition for preventing malaria infection including a protease inhibitor. A pharmaceutical composition for preventing malaria infection including a protease inhibitor and a pharmaceutical carrier. A method of malaria infection prophylaxis including the step of administering an effective amount of the composition of the present invention. A method of malaria prophylaxis by inhibiting circumsporozoite protein processing or by inhibiting a protease of a sporozoite. Methods of preventing sporozoite cell invasion or preventing circumsporozoite processing.

A composition for preventing malaria infection including a steric inhibitor of circumsporozoite protein cleavage. A pharmaceutical composition for preventing malaria infection including a steric inhibitor and a pharmaceutical carrier. A method of malaria infection prophylaxis including the step of administering an effective amount of the composition of the present invention. A method of malaria prophylaxis by sterically inhibiting circumsporozoite protein processing or by directly inhibiting a protease of a sporozoite from binding to its target. Methods of preventing sporozoite cell invasion or preventing circumsporozoite processing through steric or direct inhibition.

The invention discloses a new application of plasmodium circumsporozoite protein CSP for preparing medicaments for anti-tumor multiplication and migration. The invention successfully constructs a recombinant expression carrier pFLAG-CMV8-CSP of the CSP and transfects the recombinant expression carrier into a human liver cancer cell strain HepG2 and a colorectal cancer cell strain SW480 in a manner of liposome transfection. The research result shows that the CSP is mainly expressed in the cytoplasm of HepG2 cells, can restrain TNF-Alpha and LPS, stimulate the HepG2 cells and SW480 cells to activate NF-Kappa B and restrain the multiplication of the SW480 cells, and is further developed into a novel protein medicament for the anti-tumor multiplication and migration hopefully; and the recombinant expression carrier containing the gene of the CSP is hopefully further developed into the novel protein medicament for the anti-tumor multiplication and migration, therefore, the invention has favorable clinical application prospect.

The invention discloses a fusion protein of liver-targeting peptide and recombinant human endostatin, its preparation method and application. The present invention selects 19 amino acids that can be specifically combined with the receptor--heparan sulfate proteoglycan HSPG on the surface of liver cells in the conserved I region of the N-terminal of the Plasmodium circumsporozoite protein CSP, and uses genetic engineering to fuse it in The carboxy-terminus of the novel human endostatin nhES with 9 amino acid sequences (MGGSHHHHH) added to the amino-terminus, and the liver-targeting peptide and recombinant human endostatin fusion protein (ES‑CSP) were prepared. The fusion protein is easy to purify, can specifically target the liver to inhibit the formation of new blood vessels, increase the local concentration of the drug at the lesion site, reduce the systemic dosage, and reduce its toxic and side effects. It provides ideas and scientific basis for the clinical development of drugs that target angiogenesis to treat liver cancer, and has great scientific significance and practical value for further improving the treatment level of liver cancer in my country.

The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum circumsporozoite protein (CSP) operably linked to a human CMV promoter, and / or (b) a second adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum apical membrane antigen 1 (AMA-1) antigen operably linked to a human CMV promoter.

Methods are provided for reducing the activity or function of an inflammatory cell by contacting a cell with, or administering to a subject in need thereof, an effective amount of a circumsporozoite protein or homolog thereof, or a fragment thereof. Methods of treating an inflammatory disease, or an autoimmune disease or for inducing tolerance are also disclosed as are pharmaceutical compositions comprising a therapeutically effective amount of a circumsporozoite protein or homolog thereof, or a fragment thereof and a pharmaceutically acceptable carrier.

The invention relates to Plasmodium antigenic polypeptides identified through the use of a specifically devised functional immunization screening assay. In particular, the invention relates to antigenic polypeptides of malaria parasites wherein said antigenic polypeptides that exhibit a protective effect, especially that of eliciting a protective immune response in a host against challenge by Plasmodium sporozoites. The invention relates to a combination of compounds, comprising at least 2 distinct active ingredients wherein each active ingredient consists of an antigenic polypeptide of a Plasmodium parasite, a polynucleotide encoding the antigenic polypeptide, or a vector, in particular a viral vector, especially a lentiviral vector, expressing such antigenic polypeptide of a Plasmodium parasite, wherein one antigenic polypeptide is the circumsporozoite protein (CSP) or a polypeptidic derivative thereof and another antigenic polypeptide is either protein Ag40 (11-09) or protein Ag45 (11-10).

The invention relates to a recombinant polypeptide construct comprising epitopes from Plasmodium falciparum protein circumsporozoite protein (CSP). The epitopes contain HLA class I binding motifs and stimulate an anti-malaria CD8+T-cell response. The polypeptides can be incorporated into immunogenic formulations against malaria. Additionally, the antigens are useful for facilitating evaluation of immunogenicity of candidate malaria vaccines.